186 related articles for article (PubMed ID: 24055993)
1. The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice.
Lao C; Brown C; Obertová Z; Edlin R; Rouse P; Hodgson F; Holmes M; Gilling P; Lawrenson R
Fam Pract; 2013 Dec; 30(6):641-7. PubMed ID: 24055993
[TBL] [Abstract][Full Text] [Related]
2. Screening for prostate cancer in New Zealand general practice.
Zuzana O; Ross L; Fraser H; Charis B; Alistair S; Leanne T; Michael H; Peter G
J Med Screen; 2013 Mar; 20(1):49-51. PubMed ID: 23612467
[TBL] [Abstract][Full Text] [Related]
3. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen.
Krahn MD; Coombs A; Levy IG
CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343
[TBL] [Abstract][Full Text] [Related]
4. PSA screening in New Zealand: total population results and general practitioners' current attitudes and practices.
van Rij S; Dowell T; Nacey J
N Z Med J; 2013 Aug; 126(1381):27-36. PubMed ID: 24150262
[TBL] [Abstract][Full Text] [Related]
5. PSA testing in general practice.
Hodgson F; Obertová Z; Brown C; Lawrenson R
J Prim Health Care; 2012 Sep; 4(3):199-204. PubMed ID: 22946067
[TBL] [Abstract][Full Text] [Related]
6. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
7. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
van Vugt HA; Roobol MJ; Venderbos LD; Joosten-van Zwanenburg E; Essink-Bot ML; Steyerberg EW; Bangma CH; Korfage IJ
Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
[TBL] [Abstract][Full Text] [Related]
8. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.
Obertová Z; Scott N; Brown C; Hodgson F; Stewart A; Holmes M; Lawrenson R
BMC Fam Pract; 2014 Aug; 15():145. PubMed ID: 25154420
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
[TBL] [Abstract][Full Text] [Related]
11. Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.
Obertová Z; Hodgson F; Scott-Jones J; Brown C; Lawrenson R
J Rural Health; 2016; 32(1):56-62. PubMed ID: 26174590
[TBL] [Abstract][Full Text] [Related]
12. Difference in willingness-to-pay for prostate cancer screening between ill-informed and well-informed men: a contingent valuation survey.
Yasunaga H; Sugihara T; Imamura T
Urology; 2011 Jun; 77(6):1325-9. PubMed ID: 21507471
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
[TBL] [Abstract][Full Text] [Related]
14. Cost implications of PSA screening differ by age.
Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE
BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis of a new prostate cancer risk index for prostate cancer detection.
Nichol MB; Wu J; An JJ; Huang J; Denham D; Frencher S; Jacobsen SJ
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):253-61. PubMed ID: 21537346
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen testing in Ontario: reasons for testing patients without diagnosed prostate cancer.
Bunting PS; Goel V; Williams JI; Iscoe NA
CMAJ; 1999 Jan; 160(1):70-5. PubMed ID: 9934349
[TBL] [Abstract][Full Text] [Related]
17. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen.
Zhang HF; Wang HL; Xu N; Li SW; Ji GY; Li XM; Pan YZ; Zhang L; Zhao XJ; Gao HW
Chin Med J (Engl); 2004 Jan; 117(1):67-70. PubMed ID: 14733776
[TBL] [Abstract][Full Text] [Related]
18. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?
O'Dell KJ; Volk RJ; Cass AR; Spann SJ
J Fam Pract; 1999 Sep; 48(9):682-8. PubMed ID: 10498074
[TBL] [Abstract][Full Text] [Related]
19. Ethnic and socio-economic disparities in prostate cancer screening: lessons from New Zealand.
Matti B; Lyndon M; Zargar-Shoshtari K
BJU Int; 2021 Dec; 128 Suppl 3():11-17. PubMed ID: 32599662
[TBL] [Abstract][Full Text] [Related]
20. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
Howard K; Barratt A; Mann GJ; Patel MI
Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]